MTOR and neuroendocrine neoplasm: Interestingly, the mTOR inhibitor, Everolimus had been the therapy of choice for a meager 1% patients, which could probably relate to the approval of Everolimus for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease following the results of the RADIANT-3 trial from 2011 (24) and probably also due to the comparatively more severe toxicity profile.